Retatrutide vs Tirzepatide: A Research Comparison

Retatrutide and tirzepatide are two of the most-studied compounds in metabolic research today. Both are incretin-based, both are products of Eli Lilly’s development pipeline, and both have produced striking results in Phase 3 trials — but they are mechanistically distinct, and they are at very different stages in their respective regulatory journeys.

This article walks through the receptor profiles, the Phase 3 readouts that have been published as of the most recent reporting period, the mechanistic implications of each, and the practical considerations that matter for laboratories sourcing either compound for research. PeptivaLabs sells both compounds exclusively for research use; tirzepatide we list as TRZ and retatrutide we list as RTA in our catalog. Throughout this article, we use the full chemical names because that is how they appear in the published literature.

Nothing on this page is a clinical recommendation. Both compounds — including the FDA-approved tirzepatide — are sold by PeptivaLabs strictly as research compounds, not for therapeutic use.

Receptor Profiles, Side by Side

The clearest way to understand how these two compounds differ is to look at their receptor activity.

Tirzepatide — Dual GIP / GLP-1 receptor agonist

Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist at two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Its sequence is based on the native GIP backbone with selected substitutions that confer GLP-1 receptor activity, fatty-acid acylation that extends half-life, and resistance to DPP-4-mediated degradation. The compound was developed under the internal designation LY3298176 and reached FDA approval in 2022 as a prescription medication for type 2 diabetes (with a separate indication for chronic weight management following SURMOUNT trial data).

Retatrutide — Triple GIP / GLP-1 / glucagon receptor agonist

Retatrutide extends the dual-agonist concept by adding glucagon receptor activity. It is a 39-amino-acid peptide engineered for high-affinity binding at three receptors simultaneously: GLP-1, GIP, and glucagon. The compound was designated LY3437943 in development and is currently progressing through Phase 3 trials. As of the most recent regulatory updates available at the time of writing, retatrutide has not been approved for any indication and remains an investigational compound.

The mechanistic significance of the third receptor is the centerpiece of the retatrutide research program. Glucagon receptor agonism is associated with increased energy expenditure, increased hepatic fat oxidation, and effects on cholesterol and triglyceride metabolism that are distinct from the incretin effects mediated by GLP-1 and GIP. Whether the integrated triple-receptor profile produces synergistic effects greater than the sum of the parts — or whether the glucagon component primarily adds risk profile complexity — is the central empirical question that the Phase 3 retatrutide program is set up to answer.

Phase 3 Data: What the Published Readouts Show

Tirzepatide — SURPASS and SURMOUNT

Tirzepatide’s Phase 3 program comprises two main families of trials. The SURPASS series (SURPASS-1 through SURPASS-5, with various extensions) studied tirzepatide in type 2 diabetes, both as monotherapy and in combination with metformin, sulfonylureas, basal insulin, and other comparators. Across the program, tirzepatide produced HbA1c reductions in the range of 1.8% to 2.6%, with weight loss of approximately 7-13 kg at the highest doses (Frias et al., NEJM 2021; Rosenstock et al., Lancet 2021).

The SURMOUNT series (SURMOUNT-1 through SURMOUNT-5) studied tirzepatide in obesity without type 2 diabetes. SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight reduction of approximately 21% at the 15 mg weekly dose at 72 weeks — a magnitude of effect that was unprecedented for a non-surgical intervention at the time of publication.

Retatrutide — TRIUMPH and TRANSCEND

Retatrutide’s Phase 3 program is structured as two main programs: TRIUMPH (obesity) and TRANSCEND (type 2 diabetes), with additional studies in MASH (metabolic-dysfunction-associated steatohepatitis), obstructive sleep apnea, and cardiovascular outcomes.

The Phase 2 retatrutide obesity trial (Jastreboff et al., NEJM 2023) reported mean weight reduction of approximately 24% at 48 weeks at the highest dose, with continued downward trajectory at the trial endpoint suggesting that the steady-state effect had not yet been reached. Subsequent TRIUMPH Phase 3 readouts have reinforced and extended this picture.

The TRIUMPH-4 readout in early 2026 reported approximately 28.7% mean body-weight reduction in participants with obesity and concurrent knee osteoarthritis, framed as a study of weight loss as a disease-modifying lever for OA. The TRANSCEND-T2D-1 readout in type 2 diabetes reported HbA1c reductions of 1.7-2.0% with concurrent weight loss of 12.7-16.8% at the 40-week primary endpoint — exceeding the published tirzepatide T2D effects on weight, with comparable HbA1c effects.

Direct head-to-head: TRIUMPH-5 is a Phase 3 trial designed as a direct comparison between retatrutide and tirzepatide. As of writing, results from this trial have not been published. When TRIUMPH-5 reads out, it will be the first direct, controlled comparison of the two compounds at standardized doses and is the most-anticipated data event in this research area.

Mechanism Implications: Why the Glucagon Receptor Matters

The glucagon receptor activity that distinguishes retatrutide from tirzepatide produces several mechanistic effects that are not predicted by the GLP-1 / GIP profile alone.

Hepatic fat metabolism

Glucagon receptor activity in the liver upregulates fatty acid oxidation and reduces hepatic de novo lipogenesis. This is the primary mechanistic rationale for the SYNERGY-NASH program studying retatrutide in MASH (formerly known as NASH). Early SYNERGY readouts have reported reductions in hepatic fat content exceeding what would be expected from weight loss alone, consistent with a direct hepatic glucagon effect.

Energy expenditure

Multiple animal-model and early human studies of glucagon-receptor-active compounds have reported increased basal metabolic rate and increased energy expenditure. The retatrutide Phase 2 weight-loss data showed continued downward weight trajectory at the trial endpoint, which is consistent with a profile that combines reduced caloric intake (incretin effect) with increased caloric expenditure (glucagon effect) — a profile not seen with tirzepatide or other dual agonists.

Cholesterol and triglyceride effects

Glucagon receptor activation has been associated with reductions in LDL cholesterol and triglycerides in earlier glucagon-monoagonist research. Retatrutide trial readouts have included favorable lipid panel changes that go beyond what tirzepatide produces, though comparisons across separate trials should be made with the standard caveats about cross-trial population differences.

Tolerability and Adverse-Event Profiles in the Published Trials

Both compounds have produced predominantly gastrointestinal adverse-event profiles in the published Phase 3 data — nausea, vomiting, diarrhea, and constipation — at frequencies typical of the incretin class. Most events are mild to moderate and concentrate in the dose-titration phase.

In tirzepatide trials, the most commonly reported adverse events have been nausea (in approximately 24% of participants at the 15 mg dose), diarrhea (~17%), and vomiting (~10%) (Frias et al., NEJM 2021). Discontinuation rates due to adverse events have been in the single digits across most SURPASS and SURMOUNT studies.

In retatrutide Phase 2 and emerging Phase 3 data, the GI adverse-event frequencies are broadly comparable, with some studies suggesting a slightly higher overall rate that has not been fully resolved. Additional adverse events specific to retatrutide that may relate to the glucagon component include modest increases in heart rate at higher doses (typically 6-8 bpm at the highest dose levels in Phase 2 data) — though this signal will be characterized more fully when full Phase 3 cardiovascular data become available.

Both compounds also include the class-wide warnings associated with GLP-1 receptor agonist research, including signals around acute pancreatitis, gallbladder disease, and theoretical thyroid concerns based on rodent C-cell findings. These are prominently disclosed in the prescribing information for tirzepatide and discussed in retatrutide investigator brochures.

Practical Considerations for Research Design

Half-life

Both compounds are engineered with extended-half-life modifications. Tirzepatide has a half-life of approximately 5 days, supporting once-weekly research dosing. Retatrutide has a half-life of approximately 6 days, also supporting once-weekly dosing in research protocols. This is important for in-vivo research design and washout intervals.

Reconstitution and storage

Both compounds are typically supplied as lyophilized powder for reconstitution in bacteriostatic water for research use. Stability after reconstitution is typically 14-28 days under refrigeration depending on the formulation; both are sensitive to freeze-thaw cycles and to light. PeptivaLabs supplies stability and storage data sheets with each lot; researchers should consult those rather than relying on generalized peptide storage rules.

Purity and authentication

Both retatrutide and tirzepatide are sufficiently complex 39-amino-acid peptides that purity and identity verification matter substantially for research reproducibility. Reproducibility-focused laboratories should source only material with HPLC and mass-spectrometry verification at the lot level. PeptivaLabs publishes COAs for every batch and includes NFC-based blockchain authentication on every vial.

Sourcing RTA and TRZ for Research

PeptivaLabs lists retatrutide as RTA (20 mg vial) and tirzepatide as TRZ (20 mg vial) in our research catalog. Both are sold strictly for in-vitro research and are accompanied by per-batch HPLC and mass-spectrometry COAs, plus NFC-encoded blockchain authentication on every vial. Both ship with documented stability and reconstitution guidance.

Selected References

Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.

Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet, 2021.

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.

Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 2023.

Rosenstock J et al. Retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, in adults with type 2 diabetes (Phase 2). Lancet, 2023.

Eli Lilly and Company. TRIUMPH program disclosures and trial registry entries on ClinicalTrials.gov, 2024-2026.

Eli Lilly and Company. SYNERGY-NASH and SYNERGY-CKD program disclosures, 2024-2026.

FDA prescribing information for tirzepatide (Mounjaro and Zepbound). Most recent revision dates as published on the FDA website.